Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

1.8K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
1.8K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.7K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of the Prognostic Value of Three Different Single HLA Based Antibody Detection Assays.

HLA·2026
Same author

Lack of association between vaccine-induced immune thrombocytopenia and thrombosis and HLA loci in a large cohort.

British journal of haematology·2026
Same author

Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid Syndrome.

The New England journal of medicine·2026
Same author

Adenoviral Inciting Antigen and Somatic Hypermutation in VITT.

The New England journal of medicine·2026
Same author

Demographics and donor motivation drive declining blood donations: A 15-year study in Germany reflecting trends in high-income countries.

Vox sanguinis·2026
Same author

Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT)-like Syndrome: A Case Report and Some Considerations on a Novel Diagnostic and Therapeutic Challenge.

Diagnostics (Basel, Switzerland)·2026

Related Experiment Video

Updated: Feb 27, 2026

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
05:53

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates

Published on: July 6, 2013

15.6K

Transfusion-transmitted CMV infection - current knowledge and future perspectives.

M Ziemann1, T Thiele2

  • 1Institut für Transfusionsmedizin, Universitätsklinikum Schleswig Holstein, Lübeck, Germany.

Transfusion Medicine (Oxford, England)
|June 24, 2017
PubMed
Summary
This summary is machine-generated.

Human cytomegalovirus (CMV) transmission via transfusion (TT-CMV) remains a risk for immunocompromised patients and infants. Further studies are needed to confirm TT-CMV prevention strategies and assess alternative transmission routes.

Keywords:
CMV testingcytomegalovirustransfusion-transmitted CMV infection

More Related Videos

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

12.9K
Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
11:18

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

13.4K

Related Experiment Videos

Last Updated: Feb 27, 2026

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
05:53

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates

Published on: July 6, 2013

15.6K
Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

12.9K
Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
11:18

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

13.4K

Area of Science:

  • Transfusion Medicine
  • Virology
  • Immunocompromised Patient Care

Background:

  • Transfusion-transmitted human cytomegalovirus (TT-CMV) poses a significant risk to immunocompromised patients, including stem cell transplant recipients and low birthweight infants.
  • Current risk reduction strategies include leukocyte depletion and CMV-IgG-negative donations, but residual risk persists.
  • Donations from newly CMV-IgG-positive donors are suspected to carry the highest risk due to high CMV-DNA levels.

Purpose of the Study:

  • To evaluate the effectiveness of current TT-CMV prevention strategies.
  • To investigate the residual risk of TT-CMV with leucoreduced blood products.
  • To clarify the relative importance of alternative CMV transmission routes in at-risk populations.

Main Methods:

  • Review of clinical studies on TT-CMV risk reduction measures.
  • Analysis of data from large blood donor cohorts regarding CMV-DNA levels and antibody status.
  • Examination of presumed TT-CMV cases and alternative transmission routes.

Main Results:

  • Evidence for continued TT-CMV transmission via leucoreduced units is lacking.
  • CMV infections in low birthweight infants are primarily attributed to breast milk or congenital transmission, not transfusion.
  • The relative contribution of alternative CMV transmission routes compared to transfusion remains unclear for other at-risk patients.

Conclusions:

  • Well-designed studies are essential to guide optimal transfusion regimens for preventing TT-CMV.
  • Further investigation into presumed TT-CMV cases is required to establish definitive transmission pathways.
  • Clarifying transmission routes is crucial for protecting vulnerable patient populations.